Víctor
Quevedo Vila
Víctor Quevedo Vila-rekin lankidetzan egindako argitalpenak (9)
2022
2021
-
Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563
-
Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?
Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336
2020
-
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
Lupus, Vol. 29, Núm. 12, pp. 1556-1565
-
Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).
Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 657-662
-
Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)
Lupus, Vol. 29, Núm. 1, pp. 27-36
-
Hormonal Dependence and Cancer in Systemic Lupus Erythematosus
Arthritis Care and Research, Vol. 72, Núm. 2, pp. 216-224
2016
-
Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus
Clinical and Experimental Rheumatology, Vol. 34, pp. 40-47
-
Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry
Rheumatology (United Kingdom), Vol. 55, Núm. 7, pp. 1243-1250